Mirum Pharmaceuticals (NASDAQ:MIRM) COO Peter Radovich Sells 16,515 Shares of Stock

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) COO Peter Radovich sold 16,515 shares of the firm’s stock in a transaction dated Monday, March 16th. The shares were sold at an average price of $91.98, for a total transaction of $1,519,049.70. Following the completion of the sale, the chief operating officer owned 40,272 shares of the company’s stock, valued at $3,704,218.56. This trade represents a 29.08% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.

Peter Radovich also recently made the following trade(s):

• On Monday, February 2nd, Peter Radovich sold 2,631 shares of Mirum Pharmaceuticals stock. The stock was sold at an average price of $103.30, for a total value of $271,782.30.
• On Monday, January 26th, Peter Radovich sold 3,143 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $96.19, for a total value of $302,325.17.
• On Thursday, January 22nd, Peter Radovich sold 2,382 shares of Mirum Pharmaceuticals stock. The shares were sold at an average price of $93.33, for a total value of $222,312.06.

Mirum Pharmaceuticals Stock Performance

Shares of NASDAQ MIRM opened at $96.55 on Wednesday. The company has a current ratio of 2.67, a quick ratio of 2.55 and a debt-to-equity ratio of 0.98. The company has a market capitalization of $5.83 billion, a P/E ratio of -201.14 and a beta of 0.52. Mirum Pharmaceuticals, Inc. has a 12 month low of $36.88 and a 12 month high of $109.28. The stock has a 50 day moving average of $96.13 and a 200-day moving average of $81.00.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its quarterly earnings results on Wednesday, February 25th. The company reported ($0.11) earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.13). Mirum Pharmaceuticals had a negative net margin of 4.48% and a negative return on equity of 8.53%. The business had revenue of $148.93 million during the quarter, compared to the consensus estimate of $141.78 million. During the same quarter last year, the company posted $1.00 EPS. The firm’s revenue was up 49.8% on a year-over-year basis. As a group, equities research analysts predict that Mirum Pharmaceuticals, Inc. will post -1.43 EPS for the current year.

Analyst Ratings Changes

A number of analysts have recently issued reports on MIRM shares. Wall Street Zen cut shares of Mirum Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Saturday, February 28th. HC Wainwright upped their price target on shares of Mirum Pharmaceuticals from $102.00 to $130.00 and gave the company a “buy” rating in a research note on Monday, January 26th. Leerink Partners cut their price objective on shares of Mirum Pharmaceuticals from $120.00 to $118.00 and set an “outperform” rating for the company in a research report on Thursday, February 26th. Cantor Fitzgerald restated an “overweight” rating and set a $130.00 price objective on shares of Mirum Pharmaceuticals in a report on Monday, December 8th. Finally, Stifel Nicolaus upped their target price on Mirum Pharmaceuticals from $98.00 to $125.00 and gave the company a “buy” rating in a research report on Thursday, February 26th. One analyst has rated the stock with a Strong Buy rating, twelve have given a Buy rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $117.00.

Institutional Trading of Mirum Pharmaceuticals

Institutional investors have recently bought and sold shares of the business. Cullen Frost Bankers Inc. acquired a new position in shares of Mirum Pharmaceuticals during the 4th quarter worth approximately $30,000. Eurizon Capital SGR S.p.A. acquired a new stake in shares of Mirum Pharmaceuticals in the fourth quarter valued at approximately $32,000. CIBC Private Wealth Group LLC acquired a new stake in shares of Mirum Pharmaceuticals in the fourth quarter valued at approximately $32,000. MCF Advisors LLC boosted its stake in shares of Mirum Pharmaceuticals by 76.4% in the third quarter. MCF Advisors LLC now owns 427 shares of the company’s stock valued at $31,000 after buying an additional 185 shares during the period. Finally, Quantbot Technologies LP bought a new stake in shares of Mirum Pharmaceuticals in the third quarter valued at approximately $33,000.

Key Mirum Pharmaceuticals News

Here are the key news stories impacting Mirum Pharmaceuticals this week:

• Positive Sentiment: Mirum completed enrollment in the Phase 3 EXPAND study of LIVMARLI (maralixibat) for additional rare cholestatic liver diseases, a key clinical milestone that keeps the program on track; topline data are expected in Q4 2026. This is a material near‑term catalyst that can materially re‑rate the stock if results are positive. Mirum Completes Enrollment in Late-Stage EXPAND Study of Livmarli Mirum Completes Enrollment (Yahoo)
• Negative Sentiment: Multiple insiders (CEO Christopher Peetz, COO Peter Radovich, CFO Eric Bjerkholt, SVP Jolanda Howe and Joanne Quan) sold meaningful blocks of shares on March 16 — collectively several million dollars at an average price of ~$91.98 — reducing their holdings by double‑digit percentages. Large, clustered insider sales can be perceived as profit‑taking or concern about near‑term upside and may put pressure on the stock even though insiders still retain significant equity. SEC filings: Peetz Form 4 Radovich Form 4 Bjerkholt Form 4 Howe Form 4 Quan Form 4

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.